Latest news
Loading news…
CureVac develops mRNA-based therapies for medical applications, including cancer treatment.
CureVac was acquired by BioNTech in 2025 for $1.25B.
Total Funding
Available in Pro Last Funding
Available in Pro Acquisitions
1
Monthly Visits
Available in Pro Contacts
346
Company Details
Funding & Financials
Pro- Total funding
- Funding rounds
- Last funding
- Last funding type
- Last funding date
- Funding status
- Total equity funding
- Revenue range
Web Traffic
Pro- Monthly visits
- Global traffic rank
- 6-mo avg visits
- Visit duration (s)
- Pages / visit
- Bounce rate
- Rank change (mo)
Company Info
- Org types
- company
- HQ
- Tübingen, Baden-Wurttemberg, Germany
Acquisitions by CureVac
Loading columns…
0 of 0Show
Page 1 / 1
Key People at CureVac
Founder
Co-Founder and CSO
Chief Technology Officer
Chief Development Officer
Head of Immunotherapy
Area Head - Molecular Therapy
Chief Medical Officer
Vice President Formulation & Delivery
Co-Founder, CPO
346
professional contacts at CureVac
Contact execs at CureVac →Explore 200,000+ acquisitions — free
Filter the full database across sectors, companies, dates, and deal sizes. No signup, no paywall.
Recent News related to CureVac
Loading news…
FAQs about CureVac
People who checked this page also checked these
Sectors CureVac invests & acquires in
Browse the full Acquirezy directory.